• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PAZOPANIB Drug Record

  • Summary
  • Interactions
  • Claims
  • PAZOPANIB chembl:CHEMBL477772 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    PAZOPANIB
    GW786034
    VOTRIENT
    GW 78603
    INDAZOLYLPYRIMIDINE 13
    GW 786034
    PZP034
    chembl:CHEMBL477772
    chemidplus:444731-52-6
    drugbank:06589
    pubchem.compound:10113978
    rxcui:714438

    Drug Info:

    FDA Approval Renal cell carcinoma
    Drug Class Kinase Inhibitors
    FDA Approval approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (7 More Sources)

    Publications:

    Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep
    Maitland ML et al., 2015, Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib., Clin Cancer Res
    Xu F et al., 2013, Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II., Eur J Med Chem
    Grande E et al., 2015, Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)., Ann Oncol
    Ravi V et al., 2016, Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib., J Natl Compr Canc Netw
    Subbiah V et al., 2017, Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma., Clin Cancer Res
    Xu CF et al., 2016, HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer., Clin Cancer Res
    Motzer RJ et al., 2013, Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms., Ann Oncol
    Ball et al., 2015, Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer., Oncol. Rep.
    Malchers F et al., 2014, Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer., Cancer Discov
    Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
    Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov
    Koehler et al., 2016, TP53 mutational status is predictive of pazopanib response in advanced sarcomas., Ann. Oncol.
    Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.
    Wu et al., 2013, Identification of targetable FGFR gene fusions in diverse cancers., Cancer Discov
    Deeks, 2012, Pazopanib: in advanced soft tissue sarcoma., Drugs
    Sethakorn N et al., 2016, Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma., BJU Int
    Borad et al., 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma., PLoS Genet.
    Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.
    Pick AM et al., 2012, Pazopanib for the treatment of metastatic renal cell carcinoma., Clin Ther
    Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol
  • PAZOPANIB   HLA-B

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26546620


    Sources:
    PharmGKB FDA

  • PAZOPANIB   FLT4

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Pazopanib
    Notes

    PMIDs:
    17288876 28377484 27160228


    Sources:
    TALC MyCancerGenome TdgClinicalTrial CIViC MyCancerGenomeClinicalTrial

  • PAZOPANIB   KDR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Pazopanib
    Novel drug target Established target
    Notes

    PMIDs:
    17288876 25411163 24036042 26063633 27160228


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial CIViC MyCancerGenomeClinicalTrial PharmGKB

  • PAZOPANIB   UGT1A1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24107802


    Sources:
    PharmGKB FDA

  • PAZOPANIB   FGFR3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type urinary bladder cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    23558953 23072642 27271022


    Sources:
    JAX-CKB CIViC

  • PAZOPANIB   CYP2C8

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25504632


    Sources:
    PharmGKB

  • PAZOPANIB   FGFR2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Clinical Status case report
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    24550739 23786770


    Sources:
    DoCM CIViC

  • PAZOPANIB   PDGFRA

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    17288876


    Sources:
    TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial

  • PAZOPANIB   FLT1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Pazopanib
    Novel drug target Established target

    PMIDs:
    17288876


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial MyCancerGenomeClinicalTrial

  • PAZOPANIB   PDGFRB

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    17288876


    Sources:
    TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial

  • PAZOPANIB   NEK2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   KIT

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    17288876


    Sources:
    TALC MyCancerGenome MyCancerGenomeClinicalTrial

  • PAZOPANIB   TNK2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   HDAC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28221861


    Sources:
    CIViC

  • PAZOPANIB   LIMK1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   CDK7

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   LTK

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   PTK2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   FGFR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    24302556


    Sources:
    DTC CIViC

  • PAZOPANIB   TAOK1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   MAPK9

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   ABCG2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25504632


    Sources:
    PharmGKB

  • PAZOPANIB   FYN

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   IGF1R

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   MAP4K4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   MAPK8

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   AURKA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   CSF1R

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   LCK

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   ALK

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   AURKB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   RET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   MTOR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24625776


    Sources:
    CIViC

  • PAZOPANIB   ABL1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type thyroid cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26324075


    Sources:
    JAX-CKB

  • PAZOPANIB   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pazopanib + Vorinostat
    Indication/Tumor Type Advanced Solid Tumor
    Response Type decreased response

    PMIDs:
    26646755 25669829


    Sources:
    JAX-CKB CIViC

  • PAZOPANIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   PPARD

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   YES1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22341567


    Sources:
    PharmGKB

  • PAZOPANIB   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: PAZOPANIB

    • Version: 20-Jun-2017

    Alternate Names:
    PAZOPANIB Generic Name
    VOTRIENT Trade Name

    Drug Info:
    Drug Class Kinase Inhibitors
    FDA Approval Renal cell carcinoma

    Publications:

  • TdgClinicalTrial: PAZOPANIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • DTC: PAZOPANIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL477772 ChEMBL Drug ID

    Drug Info:

    Publications:
    Xu F et al., 2013, Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II., Eur J Med Chem

  • JAX-CKB: Pazopanib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Ball et al., 2015, Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer., Oncol. Rep.
    Wu et al., 2013, Identification of targetable FGFR gene fusions in diverse cancers., Cancer Discov
    Koehler et al., 2016, TP53 mutational status is predictive of pazopanib response in advanced sarcomas., Ann. Oncol.

  • DoCM: PAZOPANIB

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.

  • PharmGKB: pazopanib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
    Maitland ML et al., 2015, Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib., Clin Cancer Res
    Xu CF et al., 2016, HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer., Clin Cancer Res

  • CIViC: PAZOPANIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.
    Borad et al., 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma., PLoS Genet.
    Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.

  • TALC: PAZOPANIB

    • Version: 12-May-2016

    Alternate Names:
    PAZOPANIB Primary Drug Name
    PAZOPANIB Drug Generic Name
    VOTRIENT Drug Trade Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL477772

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: PAZOPANIB

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Pazopanib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21